ArticleFood science & nutrition2026
Aspirin Use Does Not Significantly Reduce the Risk of Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aspirin Use Does Not Significantly Reduce the Risk of Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of aspirin on liver fibrosis is still controversial. To further explore the effect of aspirin on liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), we conducted this study. We applied NHANES database data to evaluate the degree of liver fibrosis through fibroscan and explored the impact of aspirin on liver fibrosis in patients with MASLD from a cross-sectional study based on the American population. Considering the shortcomings of cross-sectional studies, we also applied Mendelian randomization (MR) analysis, a novel research method, to evaluate the potential causal relationship of aspirin on liver fibrosis and cirrhosis from a genetic perspective. In a cross-sectional study of the NHANES database, we did not find that aspirin significantly improved the prognosis of liver fibrosis in MASLD patients after adjusting for possible confounding biases by multivariable logistic regression analysis. Similarly, in univariate and multivariate MR analyses, we did not observe a potential causal relationship between aspirin and liver fibrosis or cirrhosis. Our study did not find that aspirin significantly reduced the risk of liver fibrosis in MASLD patients based on cross-sectional studies of the American population and genetic associations by MR analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.